Краткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективы
https://doi.org/10.21292/2075-1230-2020-98-12-57-66
Аннотация
В обзоре проанализировано 70 источников литературы. Представлены актуальные данные о препаратах, сроках, показаниях к применению, эффективности и безопасности краткосрочных схем лечения туберкулеза с множественной лекарственной устойчивостью.
Об авторах
А. Е. Русских
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Россия
Россия
Русских Анастасия Евгеньевна – научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций
127473, Москва, ул. Достоевского, д. 4
Д. М. Кутузова
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Россия
Россия
Кутузова Дарья Михайловна – лаборант-исследователь отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций
127473, Москва, ул. Достоевского, д. 4
О. В. Ловачева
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Россия
Россия
Ловачева Ольга Викторовна – доктор медицинских наук, профессор, главный научный сотрудник отдела дифференциальной диагностики и лечения туберкулеза и сочетанных инфекций
127473, Москва, ул. Достоевского, д. 4
А. Г. Самойлова
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Россия
Россия
Самойлова Анастасия Геннадьевна – доктор медицинских наук, заместитель директора по научной работе
127473, Москва, ул. Достоевского, д. 4
Тел.: +7 (495) 681-07-46
И. А. Васильева
ФГБУ «Национальный медицинский исследовательский центр фтизиопульмонологии и инфекционных заболеваний» МЗ РФ
Россия
Россия
Васильева Ирина Анатольевна – доктор медицинских наук, профессор, директор
127473, Москва, ул. Достоевского, д. 4
Тел.: +7 (495) 681-11-66
Список литературы
1. Государственный реестр лекарственных средств [Electronic resource]. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=034e2068-66a145e9-9334-453be9bfb8ac&t=(accessed: 03.11.2020).
2. О проекте endTB | endTB [Electronic resource]. URL: http://www.endtb.org/ru/node/4 (accessed: 03.11.2020).
3. Основные показатели по туберкулезу (ТБ) по России в 2015-2019 гг. [Electronic resource]. URL: https://mednet.ru/images/materials/CMT/tb_rf_osnovnye_pokazateli_2019.pdf (accessed: 12.08.2020).
4. Тарасюк И. А., Екименко А. М., Черенкова М. А., Кудлай Д. А. Опыт применения препарата Бедаквилин у больных туберкулезом с множественной лекарственной устойчивостью возбудителя в Амурской области // Туб. и болезни легких. ‒ 2018. ‒ Т. 96, № 6. ‒ С. 45-50.
5. Трубников А. Б. и др. Обоснование рациональности внедрения краткосрочных курсов лечения МЛУ ТБ больных // Молодой ученый. ‒ 2018. № 196, Т. 1. ‒ P. 52-55.
6. Эффективность лечения больных туберкулезом легких с пре-широчайшей лекарственной устойчивостью при сокращенном 12-месячном режиме химиотерапии с максимальным бактерицидным действием [Electronic resource]. URL: https://elibrary.ru/item.asp?id=30058347 (accessed: 02.11.2020).
7. A phase 2 to evaluate the efficacy, safety and tolerability of combinations of bedaquiline, moxifloxacin, pa-824 and pyrazinamide in adult subjects with drug-sensitive or multi drug-resistant pulmonary tuberculosis. ‒ Study Results ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/results/NCT02193776?term=NC-005&draw=2&rank=1 (accessed: 03.11.2020).
8. A phase 3 study assessing the safety and efficacy of bedaquiline plus PA-824 plus linezolid in subjects with drug resistant pulmonary tuberculosis ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT02333799?term=NiX+TB&draw=2&rank=1 (accessed: 03.11.2020).
9. Abidi S. et al. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis // Eur. Respir. J. European Respiratory Society. ‒ 2020. ‒ Vol. 55, № 3.
10. Ahmad N. et al. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis // Lancet. Lancet Publishing Group, 2018. ‒ Vol. 392, № 10150. ‒ P. 821-834.
11. Aung K. J. M. et al. Successful “9-month Bangladesh regimen” for multidrugresistant tuberculosis among over 500 consecutive patients // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. 2014. ‒ Vol. 18, № 10. ‒ P. 1180-1187.
12. Bastard M. et al. What is the best culture conversion prognostic marker for patients treated for multidrug-resistant tuberculosis? // Int. J. Tuberc. Lung Dis. NLM (Medline). ‒ 2019. ‒ Vol. 23, № 10. P. 1060-1067.
13. Borisov S. E. et al. Effectiveness and safety of bedaquilinecontaining regimens in the treatment of MDR- and XDR-TB: A multicentre study // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 5.
14. Campbell J. R., Menzies D. What’s next for the standard short-course regimen for treatment of multidrug-resistant tuberculosis // Am. J. Trop. Med. Hygiene. American Society of Tropical Medicine and Hygiene. ‒ 2019. ‒ Vol. 100, № 2. ‒ P. 229-230.
15. Chee C. B. E. et al. The shorter multidrug-resistant tuberculosis treatment regimen in Singapore: Are patients from South-East Asia eligible? // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 50, № 2.
16. Conradie F. et al. Treatment of highly drug-resistant pulmonary tuberculosis // N. Engl. J. Med. Massachussetts Medical Society. ‒ 2020. ‒ Vol. 382, № 10. ‒ P. 893-902.
17. Cox V., Furin J. World Health Organization recommendations for multidrug-resistant tuberculosis: Should different standards be applied? // Intern. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2017. Vol. 21, № 12. ‒ P. 1211-1213.
18. Dalcolmo M. et al. Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000-2015 // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 4.
19. Dheda K. et al. Recent controversies about MDR and XDR-TB: Global implementation of the WHO shorter MDR-TB regimen and bedaquiline for all with MDR-TB? // Respirology. Blackwell Publishing. ‒ 2018. ‒ Vol. 23, № 1. ‒ P. 36-45.
20. Diacon A. H. et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline // N. Engl. J. Med. New England Journal of Medicine (NEJM/MMS). ‒ 2014. ‒ Vol. 371, № 8. ‒ P. 723-732.
21. Doan T. N. et al. Predicting the outcomes of new short-course regimens for multidrug-resistant tuberculosis using intrahost and pharmacokinetic-pharmacodynamic modeling // Antimicrob. Agents Chemother. American Society for Microbiology. ‒ 2018. ‒ Vol. 62, № 12.
22. Dowdy D. W. et al. Of Testing and treatment: implications of implementing new regimens for multidrug-resistant tuberculosis // Clin. Infect. Dis. Oxford University Press. ‒ 2017. ‒ Vol. 65, № 7. ‒ P. 1206-1211.
23. Evaluating newly approved drugs for multidrug-resistant TB ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT02754765 (accessed: 03.11.2020).
24. Evaluating newly approved drugs in combination regimens for multidrug-resistant tb with fluoroquinolone resistance (endTB-Q) ‒ Full Text View ‒ ClinicalTrials. gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT03896685?term=endTB&draw=2&rank=1 (accessed: 03.11.2020).
25. Evaluating the safety, tolerability, and pharmacokinetics of bedaquiline and delamanid, alone and in combination, for drug-resistant pulmonary tuberculosis ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/study/NCT02583048?term=delamanid&draw=2&rank=6 (accessed: 03.11.2020).
26. FDA approves new drug for treatment-resistant forms of tuberculosis that affects the lungs | FDA [Electronic resource]. URL: https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatmentresistant-forms-tuberculosis-affects-lungs (accessed: 03.11.2020).
27. Geneva. Report of the guideline development group meeting on the use of bedaquiline in the treatment of multidrug-resistant tuberculosis.
28. Harouna S. H. et al. Short-course treatment outcomes and adverse events in adults and children-adolescents with MDR-TB in Niger // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2019. ‒ Vol. 23, № 5. ‒ P. 625-630.
29. Hong H., Budhathoki C., Farley J. E. Increased risk of aminoglycoside-induced hearing loss in MDRTB patients with HIV coinfection // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2018. ‒ Vol. 22, № 6. ‒ P. 667-674.
30. Horter S. et al. Person-centred care in practice: Perspectives from a short course regimen for multi-drug resistant tuberculosis in Karakalpakstan, Uzbekistan // BMC Infect. Dis. BioMed. Central Ltd. ‒ 2020. ‒ Vol. 20, № 1.
31. Kassa G. M. et al. Incidence and predictors of lost to follow-up among drug-resistant tuberculosis patients at University of Gondar Comprehensive Specialized Hospital, Northwest Ethiopia: A retrospective follow-up study // BMC Infect. Dis. BioMed Central Ltd. ‒ 2019. ‒ Vol. 19, № 1.
32. Kendall E. A. et al. What will it take to eliminate drug-resistant tuberculosis? // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis., 2019. Vol. 23, № 5. P. 535-546.
33. Kendall E. A., Fojo A. T., Dowdy D. W. Expected effects of adopting a 9 month regimen for multidrug-resistant tuberculosis: a population modelling analysis // Lancet Respir. Med. Lancet Publishing Group. ‒ 2017. ‒ Vol. 5, № 3. ‒ P. 191-199.
34. Kurbatova E. V. et al. Sputum culture conversion as a prognostic marker for end-of-treatment outcome in patients with multidrug-resistant tuberculosis: A secondary analysis of data from two observational cohort studies // Lancet Respir. Med. Lancet Publishing Group. ‒ 2015. Vol. 3, № 3. ‒ P. 201-209.
35. Lienhardt C. et al. Target regimen profiles for treatment of tuberculosis: A WHO document // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 1.
36. Liu Q. et al. Practical considerations to implement the shorter regimen to MDR-TB patients in China // Clini. Microbiol. Infect. Elsevier B.V. ‒ 2018. Vol. 24, № 10. ‒ P. 1035-1036.
37. Lounis N. et al. Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration // Antimicrob. Agents Chemother. American Society for Microbiology (ASM). ‒ 2006. ‒ Vol. 50, № 11. ‒ P. 3543-3547.
38. Lu P. et al. Time to sputum culture conversion and treatment outcome of patients with multidrug-resistant tuberculosis: A prospective cohort study from urban China // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 3.
39. Madan J. J. et al. Economic evaluation of short treatment for multidrug-resistant tuberculosis, Ethiopia and South Africa: The stream trial // Bull. World Health Organ. World Health Organization. ‒ 2020. ‒ Vol. 98, № 5. ‒ P. 306-314.
40. Mаryandyshev A. O. et al. Short course treatment regimens for multiple drug resistant tuberculosis in Arkhangelsk, Murmansk and Belgorod regions // Tuberc. Lung Dis. New Terra Publishing House. ‒ 2019. ‒ Vol. 97, № 7. ‒ P. 5-10.
41. Masuku S. D. et al. Managing multidrug-resistant tuberculosis in South Africa: a budget impact analysis // Int. J. Tuberc. Lung Dis. NLM (Medline). ‒ 2020. Vol. 24, № 4. ‒ P. 376-382.
42. Mpobela Agnarson A. et al. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa // Expert. Rev. Anti. Infect. Ther. Taylor and Francis Ltd. ‒ 2020. Vol. 18, № 5. ‒ P. 475-483.
43. Munoz-Torrico M. et al. Eligibility for the shorter regimen for multidrug-resistant tuberculosis in Mexico // Eur. Respir. J. European Respiratory Society. ‒ 2018. Vol. 51, № 3.
44. Nunn A. J. et al. A Trial of a shorter regimen for rifampin-resistant tuberculosis // N. Engl. J. Med. Massachussetts Medical Society. ‒ 2019. ‒ Vol. 380, № 13. ‒ P. 1201-1213.
45. Pranger A. D. et al. The role of fluoroquinolones in the treatment of tuberculosis in 2019 // Drugs. Springer International Publishing. ‒ 2019. ‒ Vol. 79, № 2. ‒ P. 161-171.
46. Rapid Communication: Key changes to treatment of multidrugand rifampicin-resistant tuberculosis (MDR/RR-TB). 2018.
47. Safety and efficacy of various doses and treatment durations of linezolid plus bedaquiline and pretomanid in participants with pulmonary TB, XDR-TB, Pre- XDR-TB or Non-responsive/Intolerant MDR-TB (ZeNix) ‒ Full Text View ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT03086486?term=ZeNix&draw=2&rank=1 (accessed: 03.11.2020).
48. Search of: delamanid ‒ List Results ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/results?cond=&term=delamanid&cntry=&state=&city=&dist= (accessed: 03.11.2020).
49. Seung K. J. et al. Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis // Clin. Infect. Dis. Oxford University Press. ‒ 2020. ‒ Vol. 71, № 2. ‒ P. 415-418.
50. Sotgiu G., Migliori G. B. Effect of the short-course regimen on the global epidemic of multidrug-resistant tuberculosis // Lancet Respir. Med. Lancet Publishing Group. ‒ 2017. ‒ Vol. 5, № 3. ‒ P. 159-161.
51. Tatés-Ortega N. et al. Loss to follow-up in patients treated for multidrug-resistant tuberculosis in Ecuador // Rev. Panam. Salud Publica/Pan Am. J. Public Heal. Pan American Health Organization, 2019. ‒ Vol. 43.
52. The evaluation of a standard treatment regimen of anti-tuberculosis drugs for patients with MDR-TB ‒ Full Text View ‒ ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT02409290?term=STREAM&draw=2&rank=2 (accessed: 03.11.2020).
53. Trébucq A. et al. Short-course regimen for multidrug-resistant tuberculosis: a decade of evidence // J. Clin. Med. MDPI AG. ‒ 2019. ‒ Vol. 9, № 1. ‒ P. 55.
54. Trebucq A. et al. Treatment outcome with a short multidrug-resistant tuberculosis regimen in nine African countries // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2018. ‒ Vol. 22, № 1. ‒ P. 17-25.
55. Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients ‒ Full Text View ClinicalTrials.gov [Electronic resource]. URL: https://clinicaltrials.gov/ct2/show/NCT03338621?term=NC-008&draw=2&rank=1 (accessed: 03.11.2020).
56. Tsang C. A. et al. Eligibility for a shorter treatment regimen for multidrug-resistant tuberculosis in the United States, 2011-2016 // Clin. Infect. Dis. Oxford University Press. ‒ 2020. ‒ Vol. 70, № 5. ‒ P. 907-916.
57. Tweed C. D. et al. Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial // Lancet Respir. Med. Lancet Publishing Group. 2019. ‒ Vol. 7, № 12. ‒ P. 1048-1058.
58. Van Der Werf M. J. et al. Eligibility for shorter treatment of multidrug-resistant tuberculosis in the European Union // Eur. Respir. J. European Respiratory Society. ‒ 2017. ‒ Vol. 49, № 3.
59. Van Deun A. et al. Gatifloxacin is superior to levofloxacin and moxifloxacin in shorter treatment regimens for multidrug-resistant TB // Int. J. Tuberc. Lung Dis. International Union against Tubercul. and Lung Dis. ‒ 2019. ‒ Vol. 23, № 9. ‒ P. 965-971.
60. Van Deun A. et al. World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward // Intern. J. Antimicrob. Agents. Elsevier B.V. ‒ 2020. ‒ Vol. 55, № 1. P. 105822.
61. Veziris N. et al. Sterilizing activity of second-line regimens containing tmc207 in a murine model of tuberculosis // PLoS One / ed. Doherty T. M. Public Library of Science. ‒ 2011. ‒ Vol. 6, № 3. ‒ P. e17556.
62. Von Groote-Bidlingmaier F. et al. Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial // Lancet Respir. Med. Lancet Publishing Group. ‒ 2019. Vol. 7, № 3. ‒ P. 249-259.
63. Walker I. F. et al. Analysis of loss to follow-up in 4099 multidrug-resistant pulmonary tuberculosis patients // Eur. Respir. J. European Respiratory Society. 2019. ‒ Vol. 54, № 1.
64. WHO Consolidated guidelines on tuberculosis, Module 4: treatment drug-resistant tuberculosis treatment [Electronic resource]. URL: https://www.who.int/publications/i/item/9789240007048 (accessed: 05.08.2020).
65. WHO | Moscow Declaration to End TB // WHO. World Health Organization, 2017.
66. WHO treatment guidelines for drug-resistant tuberculosis OCTOBER 2016 REVISION.
67. WHO | WHO consolidated guidelines on drug-resistant tuberculosis treatment // WHO. World Health Organization, 2019.
68. World Health Organization et al. Definitions and reporting framework for tuberculosis. – 2013 revision. – World Health Organization, 2013. № WHO/HTM/TB/2013.2.
69. Xia H. et al. Value of pyrazinamide for composition of new treatment regimens for multidrug-resistant Mycobacterium tuberculosis in China // BMC Infect. Dis. BioMed Central Ltd. ‒ 2020. ‒ Vol. 20, № 1. ‒ P. 19.
70. Zelnick J.R. et al. Electronic dose monitoring identifies a high-risk subpopulation in the treatment of drug-resistant tuberculosis and HIV // Clin. Infect. Dis. Oxford University Press (OUP), 2020.
Рецензия
Для цитирования:
Русских А.Е., Кутузова Д.М., Ловачева О.В., Самойлова А.Г., Васильева И.А. Краткосрочные схемы лечения больных туберкулезом с множественной лекарственной устойчивостью. Современная ситуация и дальнейшие перспективы. Туберкулез и болезни легких. 2020;98(12):57-66. https://doi.org/10.21292/2075-1230-2020-98-12-57-66
For citation:
Russkikh A.E., Kutuzova D.M., Lovacheva O.V., Samoylova A.G., Vasilyeva I.A. Short course treatment of pulmonary tuberculosis patients suffering from multiple drug resistance. The current situation and future perspectives. Tuberculosis and Lung Diseases. 2020;98(12):57-66. (In Russ.) https://doi.org/10.21292/2075-1230-2020-98-12-57-66
Просмотров: 1448
Послать статью по эл. почте 